In this edition:
PAOLA-1: Front-line olaparib maintenance prolongs survival in HRD-positive OC
SOLO-1 demonstrates survival benefit to olaparib maintenance for BRCA mutated OC
Rucaparib maintenance delays disease progression in all subgroups
PRIMA: PFS benefit to niraparib maintenance, regardless of HRD status
Overall survival results from ARIEL4
Pembrolizumab efficacious for advanced clear cell gynaecological cancer
No PFS benefit to addition of atezolizumab to chemotherapy in relapsed OC
INOVA results support sintilimab/ bevacizumab for recurrent clear cell OC
MEDIOLA: olaparib/durvalumab/ bevacizumab for BRCA mutated relapsed OC
Prevalence of HRD in newly diagnosed advanced OC
Please login below to download this issue (PDF)